Skip to content
Research Article Open access CC BY 4.0

Influence of Angiotensin Receptor Blocker (Candesartan) and Angiotensin-Converting-Enzyme Inhibitor (Enalapril) Combined with Glimepiride on Glycated Hemoglobin in Non-Insulin Dependent Diabetic Rats (NIDDM)

Abdulwahab Al-Badri, Eyad Mallah, Zainab Zakarya, Ramadan Al-Shdefat, Feras Darwish El-Hajji, Mo’ath Ifraitekh, Abeer Kharshid, Wael Abu Dayyih

Journal of Pharmaceutical Research International · pp. 40–51 · Published 9 Jun 2020

10.9734/jpri/2020/v32i930481

Abstract

Background: Antihypertensive agents like Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Converting Enzyme Blockers (ARBs) are commonly indicated for patients with both hypertension and diabetes. However, the effect of these agents on blood sugar level or glycated hemoglobin (HbA1c) is still controversial. This study aims at investigating the short, and long term effects of ACEIs and ARBs on blood sugar level and HbA1c of a group of streptozocin (STZ)-induced NIDDM rats when given in combination with Glimepiride (antidiabetic drug from Sulfonylureas group). Methods: Diabetes mellitus (DM) was induced in 100 Wistar albino adult male and female laboratory rats above 8 weeks old, and weigh between 250-300 gm by the administration of Streptozocin 75% α-anomer. Two weeks later, the 100 rats were then randomized into four groups (25 rats each). Group one was the untreated control group (received placebo only), while other groups (II, III, and IV) were treated by Glimepiride only, Glimepiride plus ARB (Candesartan), and Glimepiride plus ACEI (Enalapril) respectively. HbA1C levels were measured at baseline (pre-test/directly after randomization) to ensure that there was no significant difference between study groups at the baseline, post-test (after two weeks), and delayed-post-test (12 weeks after randomization/ 10 weeks after post-test) to measure short and long-term changes in the study groups. Results: There was no significant difference (p-values >0.05) between the four groups (groups I, II, III, and IV) in the HbA1C mean level at the beginning of this study (two-weeks after randomization and injection of STZ) (mean = 7.62 ±SD = 0.41, 7.72 ±SD = 0.48, 7.66 ±SD = 0.47, and 7.52 ±SD = 0.51respectively). However, two weeks later, treated groups (groups II, III, and IV) showed moderate reduction of HbA1C mean level compared to the untreated (placebo) group I, that was significant in groups III, and IV, and insignificant in group II (mean =7.43±SD 0.54, 6.97±SD 0.33, 6.72±SD 0.26, and 7.71 ±SD 0.44 respectively). Furthermore, treated groups (groups II, III, and IV) showed significant dramatic reduction of HbA1C mean level when compared to the untreated group (group I) (mean = 6.22 ±SD 0.51, 5.24 ±SD 0.62, 5.22 ±SD 0.13, and 7.62 ±SD 0.42 respectively).Overall, treated groups showed significantly lower HbA1C level than placebo groups. Moreover, Glimepiride + Enalapril combination showed a stronger hypoglycemic effect than the Glimepiride + Candesartan combination at post, and post-delayed tests, however, these differences were not significant. Conclusion: The addition of either ACEIs like Enalapril, or ARBs like Candesartan to Sulfonylureas like Glimepiride to in NIDDM patients will synergize its anti-diabetic effect in NIDDM subjects, and might increase the possibility of hypoglycemia. Caution and/or dose adjustment should be considered upon using these agents together in patients with hypertension along with diabetes.

Candesartan Enalapril dependent diabetic HbA1c glimepiride

References (27)

  1. 1 Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 [DOI]
  2. 2 Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 [DOI]
  3. 3 Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients [DOI]
  4. 4 Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes [DOI]
  5. 5 Diabetes mellitus and hypertension. [DOI]
  6. 6 Prediabetes diagnosis and treatment: A review [DOI]
  7. 7 Diabetes Mellitus Review [DOI]
  8. 8 The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources.
  9. 9 Effects of Antihypertensive Treatment on Insulin Sensitivity With Special Reference to ACE Inhibitors [DOI]
  10. 10 Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance [DOI]
  11. 11 Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. [DOI]
  12. 12 Islet Secretion in a New Experimental Model for Non-insulin-dependent Diabetes [DOI]
  13. 13 Streptozotocin-induced experimental diabetes in male Wistar rats.
  14. 14 Glimepiride: evidence-based facts, trends, and observations [DOI]
  15. 15 Diabetes Mellitus and Hypertension [DOI]
  16. 16 Laboratory Diagnosis of HbA1c: A Review [DOI]
  17. 17 Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. [DOI]
  18. 18 A Review on Candesartan: Pharmacological and Pharmaceutical Profile
  19. 19 Effects of Angiotensin Receptor Antagonist and Angiotensin Converting Enzyme Inhibitor on Insulin Sensitivity in Fructose-Fed Hypertensive Rats and Essential Hypertensives [DOI]
  20. 20 EFFECT OF CHRONIC TREATMENT WITH AMLODIPINE IN NON-INSULIN-DEPENDENT DIABETIC RATS [DOI]
  21. 21 The Mode of Action of the Antidiabetic Drug Glimepiride-Beyond Insulin Secretion [DOI]
  22. 22 Diabetes Mellitus and Gestational Diabetes Mellitus [DOI]
  23. 23 Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity?
  24. 24 Effective dose range of enalapril in mild to moderate essential hypertension. [DOI]
  25. 25 Candesartan in heart failure [DOI]
  26. 26 One-dimensional diffusions with discontinuous scale [DOI]
  27. 27 Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

20

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.